Treatment with thiazolidinediones

Abstract

Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists that have been commonly used in the treatment of type 2 diabetes. They have also been considered for use in individuals with metabolic syndrome as they target a number of components of the syndrome through their multiple actions that include improvements in insulin sensitivity and glycaemic control, adipocyte maturation and aspects of lipid metabolism. However, the thiazolidinediones have also been associated with a number of adverse outcomes, including effects on the cardiovascular system and bone, which have limited their use in clinical practice.